Andrew M. Griffin

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic et al. · Molecular Cancer Therapeutics · 2020 · 87 citations · Full text

Medicine, Oncology, Pharmacology +17

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules

Tim Luker, Lilian Alcaraz, Kamaldeep K. Chohan et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 58 citations

Pharmacy, Pharmacology, Toxicology +14

Preclinical Pharmacology of AZD2327: A Highly Selective Agonist of the δ-Opioid Receptor

Thomas J. Hudzik, Carla Maciag, Mark A. Smith et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 55 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of the First Orally Available, Selective K_Na1.1 Inhibitor: <i>In Vitro</i> and <i>In Vivo</i> Activity of an Oxadiazole Series

Andrew M. Griffin, Kristopher M. Kahlig, Robert J. Hatch et al. · ACS Medicinal Chemistry Letters · 2021 · 51 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist

W. A. Brown, Richard L. Leff, Andrew M. Griffin et al. · Journal of Pain · 2017 · 50 citations

Medicine, Pharmacokinetics, Pharmacology +6